Altamira Therapeutics Ltd

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q4 2022 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairman and Chief Executive Officer Covadonga Pañeda - Chief Operating Officer Conference Call Participants Operator Good morning, and welcome to the Altamira Therapeutics 2022 Results Conference Call.

Altamira Therapeutics Ltd. (CYTO) Q4 2022 Earnings Call Transcript

Management will host an investor conference call today, May 16th, at 8 a.m. Eastern Company is advancing OligoPhore™ / SemaPhore™ platform for extrahepatic RNA delivery and efficient endosomal release; expects first research collaborations with biopharmaceutical companies in 2023 Filed IND submission with FDA for AM-125 in acute vestibular syndrome ‘Showcase' RNA development programs AM-401 and AM-411 progressing in KRAS-driven cancers and rheumatoid arthritis, targeting INDs in 2024 Divestiture or partnering of legacy assets remains a key strategic focus Top-line data from full NASAR trial with Bentrio in seasonal allergic rhinitis expected in the second quarter HAMILTON, BERMUDA / ACCESSWIRE / May 16, 2023 / Altamira Therapeutics Ltd.

Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results

HAMILTON, BERMUDA / ACCESSWIRE / May 12, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for extrahepatic targets, announced that it will host its Fiscal Year 2022 Financial Results and Business Update Call on Tuesday, May 16, 2023.

Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023

Faraday Future Intelligent Electric

SaverOne 2014 Ltd

Use these tips to day trade penny stocks in 2023 The post 3 Tips for Day Trading Penny Stocks in 2023  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Tips for Day Trading Penny Stocks in 2023

Altamira Therapeutics (NASDAQ: CYTO ) stock is taking off on Thursday despite a lack of news from the RNA-based therapeutics company. There are no new press releases from Altamira Therapeutics that explain why the company's shares are rising today.

Why Is Altamira Therapeutics (CYTO) Stock Up 45% Today?

HAMILTON, BERMUDA / ACCESSWIRE / May 1, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, chairman, and CEO Thomas Meyer will be presenting at the Sidoti Micro-Cap Conference, being held virtually on May 10 - 11, 2023. Event: Sidoti Micro-Cap Virtual Conference Date: Wednesday, May 10th Time: 1:00-1:30 PM in Track 3 Webcast: https://sidoti.zoom.us/webinar/register/WN_BUoSrU7ETIGtYOKZzzSB7g Registration: Link *Please note that Company presentation date and time are subject to change.

Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11

Creative Medical Technology Holdings

National CineMedia

Use these strategies for making money with penny stocks in 2023 The post 3 Methods for Finding Penny Stocks to Buy and Hold appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Methods for Finding Penny Stocks to Buy and Hold

Detailed results from TRAVERS trial addressing acute vestibular syndrome with AM-125 (intranasal betahistine) published in Otology & Neurotology Study demonstrates proof of concept and shows good tolerability TRAVERS shows time and dose dependent acceleration of vestibular compensation and alleviation of signs and symptoms of vestibular dysfunction Altamira intends to partner or divest AM-125, part of its legacy assets, in a strategic pivot to RNA delivery technology HAMILTON, BERMUDA / ACCESSWIRE / April 12, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of the detailed results from its TRAVERS Phase 2 trial with AM-125 (intranasal betahistine) in surgery-induced acute vestibular syndrome (AVS). The peer-reviewed article was published in Otology & Neurotology, one of the leading journals in scientific and clinical inner ear research.

Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal

Altamira Therapeutics (NASDAQ: CYTO ) stock is taking off on Wednesday after providing an update on its SemaPhore nanoparticle technology. According to a press release from Altamira Therapeutics, SemaPhore has the potential to serve the mRNA applications market.

Why Is Altamira Therapeutics (CYTO) Stock Up 64% Today?

Altamira's peptide-based SemaPhore™ nanoparticle technology confers great stability to mRNA, is non-immunogenic and non-toxic, enabling delivery to extrahepatic targets and efficient endosomal release Continued momentum in mRNA vaccines and therapeutics with over 840 programs under development, according to fresh data from Beacon RNA database by Hanson Wade Limitations of hitherto dominant lipid nanoparticle (LNP) technologies call for alternate mRNA delivery solutions HAMILTON, BERMUDA / ACCESSWIRE / April 11, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing RNA-based therapeutics that address important unmet medical needs, positions its peptide-based SemaPhore™ nanoparticle technology as a versatile and efficient alternative to the hitherto dominant lipid nanoparticle (LNP) delivery technologies in the fast growing field of mRNA (messenger ribonucleic acid) applications. According to fresh data from the Beacon RNA database by Hanson Wade, the number of mRNA vaccines and therapeutics under development has now grown to more than 840, of which 356 are using some sort of LNP for delivery.

Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles

Nektar Therapeutics

Sirius XM Holdings Inc

Virios Therapeutics

Penny stocks, the stock market game & what traders are watching this week. The post 4 Penny Stocks To Watch If You're Playing The “Stock Market Game” appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch If You're Playing The “Stock Market Game”

Published meta-analysis shows statistically significant improvement in dizziness handicap for betahistine treatment over standard of care procedure alone in patients suffering from BPPV Altamira to file IND application for intranasal betahistine (AM-125) with FDA in May 2023, including protocol for Phase 2 clinical trial in BPPV Altamira intends to partner or divest AM-125 as part of its legacy assets in a strategic pivot to its RNA delivery technology platforms HAMILTON, BERMUDA / ACCESSWIRE / April 10, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today reported highlights from a peer reviewed article showing efficacy of oral betahistine in the treatment of posterior canal benign paroxysmal positional vertigo (BPPV) when administered along with a canal repositioning procedure, the Epley maneuver. The article was published in the journal Medicine[1] and describes the results from a meta-analysis of nine randomized controlled trials with 860 posterior canal BPPV patients, of which 432 were treated with Epley's maneuver plus betahistine, and 428 solely underwent Epley's maneuver.

Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo

HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing RNA-based therapeutics that address important unmet medical needs, today announced the release of animal data by a Washington University School of Medicine (St. Louis, MO) research group showing restriction of tumor growth with a novel mRNA therapeutic delivered in nanoparticles based on the Company's SemaPhore™ delivery platform.

Altamira Therapeutics' SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model

Data to be presented at Osteoarthritis Research Society International World Congress in Denver March 17-20, 2023 Animal study shows effective attenuation of osteoarthritis progression and functional improvement in mice treated with DNMT3B mRNA nanoparticles based on Altamira's SemaPhore™ delivery technology HAMILTON, BERMUDA / ACCESSWIRE / March 15, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing RNA-based therapeutics that address important unmet medical needs, today announced the upcoming presentation of animal data generated by a leading US-based osteoarthritis research group. The data show effective attenuation of osteoarthritis progression through treatment with an mRNA therapeutic, delivered in nanoparticles based on the Company's SemaPhore™ delivery platform.

Altamira Therapeutics' SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model

SoundHound AI Inc

Wish

Use these tips for setting penny stocks investing expectations The post How to Set Expectations For Penny Stocks Trading  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Set Expectations For Penny Stocks Trading

Bentrio® remained detectable by fluorescence for up to 210 minutes in subjects' nasal passages vs. 60 minutes with saline nasal spray control Long nasal residence time supports extended protective effects against airborne allergens and other potentially harmful particles HAMILTON, BERMUDA / ACCESSWIRE / March 3, 2023 / Altamira Therapeutics Ltd.

Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties

HAMILTON, BERMUDA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company developing RNA-based therapeutics that address important unmet medical needs, today announced that it has filed a provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company's OligoPhore™ platform and a single siRNA sequence.

Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

House dust mite study shows statistically significant reduction in symptoms vs. no protection Grass pollen study shows faster onset of action and superior efficacy ratings by patients Bentrio® shows wider nasal cavity distribution, for 3.5 x more time, vs saline spray HAMILTON, BERMUDA / ACCESSWIRE / February 14, 2023 / Altamira Therapeutics Ltd.

Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ing

New, trends and future of RNA-based therapeutics Company's OligoPhoreTM / SemaPhoreTM polyplexes provide for efficient delivery of siRNA payloads into extrahepatic target cells Company's latest research and insights into RNA-based therapies Alternatives to LNPs and how Altamira's proprietary R&D is different from lipid-based solutions HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing RNA-based therapeutics that address important unmet medical needs, today announced that it will be presenting at both the 14th Annual RNA Therapeutics Conference in London February 8-9, and at the 4th Annual RNAi Based Therapeutics Summit in Boston March 21-23, 2023.

Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023

HAMILTON, BERMUDA , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR) and acute COVID-19. Bentrio nasal spray is intended to help protect against airborne allergens and viruses.

Altamira Therapeutics Provides Update on Clinical Trials with Bentrio

Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will be presenting at the 2 nd Annual mRNA-Based Therapeutics Summit Europe Conference in Berlin, Germany, which will be held January 24-26, 2023.

Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th

Hamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Provides Year - End 2022 Business Update

Altamira Therapeutics Provides Year-End 2022 Business Update

Swift progress of study enrollment - midpoint of 50 patients reached Interim analysis confirmed target enrollment of 100 patients Completion of enrollment expected by early January 2023 HAMILTON, BERMUDA / ACCESSWIRE / December 2, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has reached the midpoint for enrollment in its "NASAR" clinical trial with Bentrio in Season Allergic Rhinitis (SAR).

Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia

HAMILTON, BERMUDA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided a business update and reported its first half 2022 financial results.

Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results

Hamilton, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its licensee and distribution partner Nuance Pharma has launched its Bentrio nasal spray in Hong Kong.

News for Altamira Therapeutics Ltd Stock (CYTO)